Jingqin Zhizao
精勤智造
Jingqin Zhizao (精勤智造) is a medical technology company in Dalton Venture's portfolio, operating in the medical robotics and healthcare innovation space. Dalton Venture invested in the company in 2023 alongside a cluster of other medical device and healthcare technology firms including 星辰海医疗 (Starsea Medical), 博创生物 (Bochuang Bio), 冰晶智能 (Bingjing Intelligence), 馥逸医疗 (Fuyi Medical), 博瑞迪 (Boruidi), 瀚辰光翼 (Hanchen Guangyi), and 犀燃医疗 (Xiran Medical) — a group spanning neurointervention, endoscopy, medical robotics, seed technology, and ophthalmic surgical equipment .
elsewhere's corpus does not contain additional detail on Jingqin Zhizao's specific products, founding date, or team beyond this portfolio placement.
AI-generated — may contain errors, please verify.
Coverage
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
VBData Exclusive | Dalton Venture: The Next Phase of Opportunities in Healthcare — "Technology + Safety" Is the Unavoidable Theme
In a turbulent environment, most investment firms have chosen to play it safe, pulling back on deal activity. Yet in 2023 — widely called a funding winter — Dalton Venture actually picked up its investment pace. How does the firm see 2024 shaping up? At the start of the new year, Sun Qi, founding and managing partner of Dalton Venture, sat down with VBData to share his outlook on healthcare trends for 2024 and his advice for founders.
